| 2014 | Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials
| ANNALS OF ONCOLOGY |
| 1996 | Overexpression of c-ErbB-2 Protein in Gastric Cancer by Immunohistochemical Stain | ONCOLOGY |
| 2012 | Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy
| PLOS ONE |
| 1997 | P-glycoprotein: The intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer | BREAST CANCER RESEARCH AND TREATMENT |
| 2016 | p16 Hypermethylation and KRAS Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients with Metastatic Colorectal Cancer
| CANCER RESEARCH AND TREATMENT |
| 2021 | p16 methylation is a potential predictive marker for abemaciclib sensitivity in gastric cancer | BIOCHEMICAL PHARMACOLOGY |
| 1998 | p53 유전자 변형이 발생한 위암세포주에서 유전자이상 교정에 의한 항암제 감수성 변화
| Journal of the Korean Cancer Association (대한암학회지) |
| 2003 | Paclitaxel and Cisplatin Combination Chemotherapy in Pretreated Breast Cancer
| CANCER RESEARCH AND TREATMENT |
| 2015 | Pain palliation in patients with bone metastases using magnetic resonance-guided focused ultrasound with conformal bone system: a preliminary report.
| YONSEI MEDICAL JOURNAL |
| 2024 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer
| ESMO OPEN |
| 2012 | Patterns of regional recurrence after curative D2 resection for stage III (N3) gastric cancer: implications for postoperative radiotherapy | RADIOTHERAPY AND ONCOLOGY |
| 2023 | PBRM1-deficient PBAF complexes target aberrant genomic loci to activate the NF-κB pathway in clear cell renal cell carcinoma | NATURE CELL BIOLOGY |
| 2022 | PD-L1 expression and overall survival in Asian and western patients with gastric cancer | FUTURE ONCOLOGY |
| 2023 | Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial | LANCET ONCOLOGY |
| 2023 | Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial | LANCET |
| 2021 | Pemetrexed plus cisplatin in patients with previously treated advanced sarcoma: a multicenter, single-arm, phase II trial
| ESMO OPEN |
| 2013 | Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2013 | Pharmacogenomic Assessment of Outcomes of Pemetrexed-Treated Patients with Adenocarcinoma of the Lung
| YONSEI MEDICAL JOURNAL |
| 2021 | Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations
| INVESTIGATIONAL NEW DRUGS |
| 2023 | Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms
| FRONTIERS IN ONCOLOGY |
| 2009 | Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies. | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 1998 | Phase I clinical trial: pharmacokinetics of a novel anthracycline, DA-125 and metabolites. Single dose study | INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS |
| 2020 | Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma
| JOURNAL OF CLINICAL ONCOLOGY |
| 2008 | Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer | RADIOTHERAPY AND ONCOLOGY |
| 1994 | Phase Ib clinical trial and pharmacokinetic evaluation of recombinant human granulocyte-macrophage colony stimulating factor(rh GM-CSF LBD-005) in advanced cancer patients with chemotherapy induced myelosuppression
| Journal of the Korean Cancer Association(대한암학회지) |
| 2022 | Phase II Clinical Trial of Eribulin-Gemcitabine Combination Therapy in Previously Treated Patients With Advanced Liposarcoma or Leiomyosarcoma | CLINICAL CANCER RESEARCH |
| 2014 | Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2014 | Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma | JOURNAL OF CLINICAL ONCOLOGY |
| 2008 | Phase II study of combination chemotherapy of 5-fluorouracil, low-dose leucovorin, and oxaliplatin (FLOX regimen) in pretreated advanced gastric cancer
| ANNALS OF ONCOLOGY |
| 2015 | Phase II study of gemcitabine and vinorelbine as second- or third-line therapy in patients with primary refractory or platinum-resistant recurrent ovarian and primary peritoneal cancer by the Korean Cancer Study Group (KCSG)_KCSG GY10-10 | GYNECOLOGIC ONCOLOGY |
| 2010 | Phase II study of preoperative chemoradiotherapy (CRT) with irinotecan plus S-1 in locally advanced rectal cancer | RADIOTHERAPY AND ONCOLOGY |
| 2012 | Phase II study of the safety and efficacy of temsirolimus in East Asian patients with advanced renal cell carcinoma | JAPANESE JOURNAL OF CLINICAL ONCOLOGY |
| 2015 | Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2012 | Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma. | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2012 | Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.
| CANCER |
| 2013 | Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma
| ANNALS OF ONCOLOGY |
| 2019 | Phase II trial of preoperative sequential chemotherapy followed by chemoradiotherapy for high-risk gastric cancer | RADIOTHERAPY AND ONCOLOGY |
| 2008 | Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up.
| ANNALS OF ONCOLOGY |
| 2009 | Phospholipase C delta 1 is a novel 3p22.3 tumor suppressor involved in cytoskeleton organization, with its epigenetic silencing correlated with high-stage gastric cancer. | ONCOGENE |
| 1998 | Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients | BREAST CANCER RESEARCH AND TREATMENT |
| 2013 | PIK3CA Mutations in Hepatocellular Carcinoma in Korea
| YONSEI MEDICAL JOURNAL |
| 2015 | PINCH-2 presents functional copy number variation and suppresses migration of colon cancer cells by paracrine activity | INTERNATIONAL JOURNAL OF CANCER |
| 2009 | Postoperative adjuvant chemotherapy of gastric cancer: scrutiny into the clinical evidence based on quality assessment of medical literature of randomized controlled trials | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2009 | Prediction of high-risk patients by genome-wide copy number alterations from remaining cancer after neoadjuvant chemotherapy and surgery. | INTERNATIONAL JOURNAL OF ONCOLOGY |
| 2013 | Prediction of metachronous multiple primary cancers following the curative resection of gastric cancer
| BMC CANCER |
| 2009 | Prediction of recurrence of early gastric cancer after curative resection | ANNALS OF SURGICAL ONCOLOGY |
| 2011 | Predictive values of 5-fluorouracil pathway genes for S-1 treatment in patients with advanced gastric cancer | ANTI-CANCER DRUGS |
| 2011 | Prevalence and associated factors of psychological distress among Korean cancer patients | GENERAL HOSPITAL PSYCHIATRY |
| 2017 | Prevalence and prognostic implications of psychological distress in patients with gastric cancer
| BMC CANCER |
| 2015 | Prevalence of human papillomavirus infection and RAS mutation in sporadic keratoacanthoma | INTERNATIONAL JOURNAL OF DERMATOLOGY |
| 2023 | Prior antibiotic administration disrupts anti-PD-1 responses in advanced gastric cancer by altering the gut microbiome and systemic immune response
| CELL REPORTS MEDICINE |
| 2022 | Probe-Based Confocal Laser Endomicroscopy versus White-Light Endoscopy with Narrow-Band Imaging for Predicting and Collecting Residual Cancer Tissue in Patients with Gastric Cancer Receiving Chemotherapy
| CANCERS |
| 2021 | PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer | JOURNAL OF CLINICAL ONCOLOGY |
| 2009 | Prognosis of pN3 stage gastric cancer
| CANCER RESEARCH AND TREATMENT |
| 2011 | Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib.
| EXPERIMENTAL AND THERAPEUTIC MEDICINE |
| 2007 | Prognostic impact of resection margin involvement after extended (D2/D3) gastrectomy for advanced gastric cancer: A 15-year experience at a single Institute | JOURNAL OF SURGICAL ONCOLOGY |
| 2014 | Prognostic implications of anaplastic lymphoma kinase gene aberrations in rhabdomyosarcoma; an immunohistochemical and fluorescence in situ hybridisation study | JOURNAL OF CLINICAL PATHOLOGY |
| 2016 | Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma
| BMC CANCER |
| 2016 | Prognostic implications of PIK3CA amplification in curatively resected liposarcoma
| ONCOTARGET |
| 2018 | Prognostic implications of polycomb proteins ezh2, suz12, and eed1 and histone modification by H3K27me3 in sarcoma.
| BMC CANCER |
